Back to top
more

Nektar Therapeutics (NKTR)

(Delayed Data from NSDQ)

$1.70 USD

1.70
1,443,556

-0.05 (-2.86%)

Updated May 21, 2024 04:00 PM ET

After-Market: $1.70 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 248)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Nektar (NKTR) Q4 Earnings & Revenues Top Estimates, Stock Up

Nektar (NKTR) reports encouraging fourth-quarter results. The company continues to progress with its pipeline candidates.

Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates

Nektar (NKTR) delivered earnings and revenue surprises of 7.25% and 28.57%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for AstraZeneca (AZN) This Earnings Season?

AstraZeneca's (AZN) fourth-quarter results are expected to reflect the impact of new drug sales.

Alkermes (ALKS) to Report Q4 Earnings: What's in Store?

We expect Alkermes (ALKS) to provide revenue updates on its proprietary marketed products and pipeline candidates when it releases fourth-quarter earnings on Feb 13.

Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?

Zoetis Inc. (ZTS) will provide financial numbers for fourth-quarter 2019 and pipeline updates on Feb 13.

Nektar Therapeutics (NKTR) Stock Sinks As Market Gains: What You Should Know

Nektar Therapeutics (NKTR) closed at $22.81 in the latest trading session, marking a -0.52% move from the prior day.

Nektar's Pain Drug Gets Adverse Advisory Committee Decision

Nektar (NKTR) to stop development of chronic pain candidate, NKTR-181, following two FDA advisory committees' decision to not recommend its approval.

Nektar Up 25% as Bristol-Myers Expands Bempeg Collaboration

Nektar (NKTR) agrees to a new joint development plan with Bristol-Myers to include two new registrational studies to evaluate bempegaldesleukin plus Opdivo in bladder cancer and adjuvant melanoma.

Sweta Killa headshot

Trade Deal Optimism Fuels Santa Rally: ETFs & Stocks to Bet On

Trade deal optimism coupled with the Santa Claus rally have turned the market super bullish for the last five trading days left this year.

Maharathi Basu headshot

5 Losing Stocks From 2019 to Rebound Next Year

The positive sentiment witnessed by Wall Street in 2019 might be prevalent in 2020 as well owing to multiple tailwinds.

Why Is Nektar (NKTR) Up 6.2% Since Last Earnings Report?

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Company News For Nov 12, 2019

Companies In The News Are: QRTEA, FOLD, NKTR, WBA, KKR.

Nektar (NKTR) Q3 Earnings & Revenues Top Estimates, Stock Up

Nektar's (NKTR) reports encouraging third-quarter results. The company continues to progress with its pipeline candidates. However, the timeline for its pain drug NKTR-181's approval remains uncertain.

Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates

Nektar (NKTR) delivered earnings and revenue surprises of 23.29% and 11.46%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nektar's Shares Drop on Rating Downgrade by Goldman Sachs

Nektar (NKTR) continues its downfall in 2019. Goldman Sachs downgrades the company's rating from Buy to Sell.

Company News For Sep 30, 2019

Companies In The News Are: WFC,PFE,LTM,DAL,LVS,NKTR

Nektar Stock Down on Disappointing Breast Cancer Study Data

Nektar Therapeutics (NKTR) presents preliminary data on triple negative breast cancer patients from an early-stage study, which fails to impress investors.

Why Is Nektar (NKTR) Down 42.5% Since Last Earnings Report?

Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Nektar (NKTR) Q2 Earnings Beat Estimates, Revenues Miss

Nektar's (NKTR) reports narrower-than expected loss in the second quarter but stock declines.

Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates

Nektar (NKTR) delivered earnings and revenue surprises of 21.25% and -10.24%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy Nektar (NKTR) Ahead of Earnings?

Nektar (NKTR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?

Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is a Beat in Store for Nektar (NKTR) This Earnings Season?

The focus will be on Nektar Therapeutics' (NKTR) pipeline progress and launch plans for NKTR-181 when the company reports second-quarter results.

Can GW Pharmaceuticals (GWPH) Deliver a Beat in Q2 Earnings?

On GW Pharmaceuticals' (GWPH) second-quarter conference call, investor focus will be on the initial sales uptick of its newly launched anti-epileptic drug Epidiolex.